Friday, November 6, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

Dr. Meghana Singh

Dr. Meghana Singh

West Virginia University School of Medicine, WVU Cancer Institute

Meghana Singh, MD, is an Assistant Professor of Medicine at the West Virginia University School of Medicine and a medical oncologist with the WVU Cancer Institute, specializing in gastrointestinal malignancies. She received her medical degree from Osmania Medical College, completed her internal medicine residency at the University of Connecticut—where she also served as Chief Resident—and pursued fellowship training in hematology and oncology at the University of Pittsburgh Medical Center. During fellowship, she was selected to participate in the prestigious ASCO–AACR Clinical Trials Workshop and the ASCO SCION Workshop. Her academic interests include clinical trials, translational research, and improving access to high-quality cancer care across academic and community settings.

Published Articles (2)

Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer

June 24, 2026

For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.

Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside

January 27, 2026

Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.